Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_40_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
13 Мб
Скачать
☆
48
https://t.me/medicina_free
CHAPTER 3 | STOMACH AND DUODENAL DISORDERS
17. A 34- year- old woman presented with nausea, intermittent vomiting, bloating, and 5kg weight loss over three months. She had gastro­oesophageal reux disease, for which she took omeprazole, but no other past medical history. Examination revealed epigastric distension and a succussion splash.
Investigations:
Haemoglobin 130 g/ L Creatinine 67 µmol/ L Thyroid stimulating hormone 1.16 munit/ L Fasting glucose 4.5mmol/ L Gastroscopy Normal MR enterography Normal
What is the most appropriate investigation to make a diagnosis?
A. 3C breath testing
B. Barium follow through
C. Scintigraphic gastric emptying at two hours
D. Scintigraphic gastric emptying at four hours
E. Wireless capsule motility testing
18. A 68- year- old man with Parkinson’s disease on levodopa was admitted with vomiting and abdominal pain.
Which of the following anti- emetics is the rst- line treatment for nausea and vomiting in patients with Parkinson’s disease?
A. Domperidone
B. Haloperidol
C. Metoclopromide
D. Ondansetron
E. Prochlorperazine
19. A 45- year- old woman attended her general practitioner with recurrent nausea and vomiting associated with travel. She had tried cyclizine to no eect.
What is the next choice of medication for her motion sickness?
A. Betahistine
B. Hyoscine
C. Metoclopromide
D. Ondansetron
E. Prochlorperazine
CHAPTER 3 | QUESTIONS
https://t.me/medicina_free
20. A 56- year- old man was referred for a gastroscopy with symptoms of dyspepsia and upper abdominal pain. His history included coeliac disease (CD) for which he maintained a gluten- free diet.
Investigations:
Gastroscopy Fig. 3.6 Urease breath test Negative
49
Fig.3.6 Endoscopic image of stomach. See also Plate 8
Image courtesy of Dr Tim Ambrose, Oxford University Hospitals NHS Foundation Trust
What is the most likely diagnosis?
A. Granulomatous gastritis
B. Haemorrhagic gastritis
C. H.pylori- associated gastritis
D. Lymphocytic gastritis
E. Upper GI Crohn’s disease
50
https://t.me/medicina_free
CHAPTER 3 | STOMACH AND DUODENAL DISORDERS
21. A 56- year- old man was referred to the gastroenterology clinic with epigastric pain, anorexia, and weight loss. Abdominal examination was unremarkable. He had peripheral oedema to the mid shins.
Investigations:
Haemoglobin 130 g/ L White cell count 9.0 × 109/ L Platelet count 387 × 109/ L Albumin 28 g/ L C- reactive protein 9 mg/ L Gastroscopy Markedly thickened gastric folds primarily of the
body and fundus. Gastric biopsies taken.
Histology Foveolar hyperplasia
What is the most likely diagnosis?
A. Chronic gastritis
B. Gastric adenocarcinoma
C. Lymphoma
D. Ménétrier’s disease
E. Zollinger– Ellison syndrome
22. A patient had undergone a gastroscopy to investigate iron- deciency anaemia. Their GP had received the duodenal histology result showing ‘intraepithelial lymphocytosis and normal villous architecture’, and asked whether this meant that the patient had coeliac disease.
In which other condition can duodenal intraepithelial lymphocytosis be present?
A. All the listed options
B. Crohn’s disease
C. Giardiasis
D. NSAID enteropathy
E. Small intestinal bacterial overgrowth
CHAPTER 3 | QUESTIONS
https://t.me/medicina_free
23. A 69- year- old man was referred for a gastroscopy and colonoscopy to investigate iron deciency anaemia. He denied any symptoms. His background included ischaemic heart disease and hypertension.
Investigations:
Gastroscopy A mass was seen in the second part of the
duodenum (Fig. 3.7)
Histology (duodenal mass) Small tubular glands lined by eosinophilic
absorptive epithelium with pseudostratied hyperchromatic nuclei; no evidence of dysplasia. CD10 and CDX positive
Colonoscopy Sigmoid diverticulae only
51
Fig.3.7 Endoscopic image of second part of duodenum. See also Plate 9
Image courtesy of Dr Tim Ambrose, Oxford University Hospitals NHS Foundation Trust
What is the most likely diagnosis?
A. Coeliac disease
B. Crohn’s disease
C. Duodenal adenocarcinoma
D. Duodenal adenoma
E. Duodenal lymphoma
52
https://t.me/medicina_free
CHAPTER 3 | STOMACH AND DUODENAL DISORDERS
24. At the latest endoscopy user group meeting, the key performance measures for upper GI endoscopy are published for each endoscopist.
Which of the following is a key performance measure for gastroscopy?
A. Accurate documentation of indications after therapeutic upper gastrointestinal (UGI)
endoscopy
B. Accurate photo documentation of anatomical landmarks and abnormal ndings
C. Documentation of distance from incisors to gastro oesophageal junction (GOJ), in
centimetres
D. Documentation of patient comfort score
E. Minimum seven- minute procedure time for index gastroscopy
25. A 57- year- old taxi driver with pancreatic cancer attended the emergency department with profuse vomiting and metabolic alkalosis. Asuccussion splash was elicited on examination.
Investigations:
CT abdomen and pelvis Distended stomach with evidence of gastric outlet
obstruction secondary to duodenal obstruction
What is the most appropriate immediate next step?
A. Decompression with large- bore nasogastric tube
B. Gastrojejunostomy
C. Gastroscopy and duodenal stent insertion
D. Gastroscopy and nasojejunal tube insertion
E. Parenteral nutrition
from locally advanced pancreatic cancer
https://t.me/medicina_free
chapter
STOMACH AND DUODENAL DISORDERS
3
ANSWERS
1. E. Urea breath test
• NSAIDs and H.pylori are independent risk factors for PUD
• Routine testing and treating of H.pylori prior to starting NSAIDs is indicated in those with a history of PUD
NSAIDs and H.pylori are independent risk factors for PUD. However, both can have additive eects on the risk of peptic ulcer bleeding. Studies have shown that H.pylori eradication is associated with a reduced incidence of peptic ulcer in new NSAID users but not in chronic users. Atest and treat strategy is not recommended in all patients prior to starting NSAIDs. However, it is justiable in those with a history of PUD.
Full- dose PPIs in high- risk patients (age >60, past history of PUD, concomitant oral steroids or oral anticoagulants, comorbidity, and requirement for prolonged use of NSAIDs) is recommended. COX– 2 inhibitors, such as celecoxib, have fewer GI side eects. However, their use has to be balanced against the recognized risk of cardiovascular events.
Malfertheiner P, Megraud F, O’Morain CA etal. (on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel). Management of Helicobacter pylori infection— the Maastricht V/ Florence Consensus Report. Gut. 207 Jan;66():6– 30. Doi:0.36/ gutjnl- 206- 32288.
2. B. H.pylori infection
• Rapid urease testing may give false negative results in patients on PPI therapy
• PPI therapy is associated with an elevated serum gastrin
Rapid urease testing (e.g. a CLO test) sensitivity is well recognized as being compromised by acid­suppressing therapy, and patients should ideally withhold these medications for two weeks prior to testing. If patients are still taking their medication at the time of endoscopy, there is a risk of obtaining false negative results. PPI treatment is also associated with an elevated serum gastrin due to the interruption of the normal negative feedback loop.
The most likely diagnosis is of a false negative rapid urease test in a patient with H.pylori infection, and this patient should be oered non- invasive H.pylori testing o PPI treatment.
ZES is a cause of peptic ulceration in 0.%– % of cases. Features suggestive of ZES include:
• severe or resistant ulceration in the absence of NSAIDs or H.pylori infection
• unusual sites of ulceration (e.g. D2 or more distally)
• diarrhoea
Best of Five MCQs for the European Specialty Examination in Gastroenterology and Hepatology. Thomas Marjot, Colleen G C McGregor, Tim Ambrose, Aminda N De Silva, Jeremy Cobbold, and Simon Travis, Oxford University Press (2021). © Oxford University Press. DOI: 10.1093/oso/9780198834373.003.0003
54
https://t.me/medicina_free
CHAPTER 3 | STOMACH AND DUODENAL DISORDERS
• large gastric folds
• fasting serum gastrin levels >,000 pg/ ml (o PPI treatment)
Fasting serum gastrin levels can be intermediate in ZES so, if there is strong suspicion clinically, the next step would be a secretin provocation test. Other causes of intermediate elevated fasting serum gastrin levels include atrophic gastritis, pernicious anaemia, gastric outlet obstruction (GOO), renal failure, and small bowel resection.
HIV infection predisposes to cytomegalovirus (CMV) and herpes simplex virus, which can cause ulcers resistant to standard treatment. Crohn’s disease is characterized by transmural ulceration, although this is uncommon in the upper GI tract. Tuberculosis is a rare cause of ulceration. The normal blood tests make these diagnoses less likely.
Malfertheiner P, Megraud F, O’Morain CA etal. (on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel). Management of Helicobacter pylori infection— the Maastricht V/ Florence Consensus Report. Gut. 207 Jan;66():6– 30. Doi:0.36/ gutjnl- 206- 32288.
3. C. Low body mass index
• Failure of rst- line H.pylori eradication regimens occurs in at least 20% of patients
• Insucient gastric acid suppression contributes signicantly to treatment failure
• Raised BMI and active smoking confer lower eradication rates due to reduced drug bioavailability
Failure of rst- line treatment regimens occurs in more than 20% of patients. Contributory factors are multifactorial:host genetic factors, H.pylori virulence factors, antimicrobial resistance, compliance with therapy, and duration of therapy.
Factors associated with treatment failure are discussed below:
• Primary antimicrobial resistance is increasing worldwide. Resistance patterns vary between regions because of diering antibiotic usage, treatment regimens, and disease prevalence. Amoxicillin rates are low in Europe, the US, Japan, and China in contrast to signicantly higher rates in South Korea and Iran. Clinicians must bear in mind the primary antimicrobial resistance patterns for their local population before deciding on empirical treatment.
• Acid suppression studies show that higher- dose twice- daily PPI regimens are associated with a higher eradication rate when compared with standard regimens. Intra- gastric acid suppression enables H.pylori to enter its growth phase, thereby increasing its vulnerability to antibiotics targeting its replicative cycle.
• Virulence factors of H.pylori:certain H.pylori strains produce highly immunogenic CagA protein and VacA toxin, both of which result in more severe gastric inammation. Studies signicantly correlate severe gastric inammation with treatment success. It is postulated that severe inammation increases drug bioavailability through increased mucosal perfusion.
• Host IL- β polymorphism:eradication rates are signicantly better in patients with the IL- β- 5 T/ T genotype compared with the C/ C and C/ T genotypes.
• BMI and smoking:an elevated BMI (>25kg/ m2) and smoking are associated with lower eradication rates, thought to be due to lower drug bioavailability.
• Treatment duration:a longer treatment duration (0– 4days) is more ecacious than a seven- day regimen, with eradication rates increased by 4%– 6%.
Song M, Ang T.Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol. 204 Feb 4; 20(6):57– 528. Doi:0.3748/ wjg.v20.i6.57.
CHAPTER 3 | ANSWERS
Billroth I gastrectomy for gastric ulcer
not stomach
https://t.me/medicina_free
55
4. E. Resection of the gastric antrum, formation of a gastrojejunostomy, and closure of the rst part of the duodenum and gastric outow
A. Is as described B. Is a vagotomy and pyloroplasty C. Is a Roux- en- Y gastric bypass D. Is a pyloromyotomy.
Fig. 3.8 shows both the Billroth Iand Billroth II gastrectomy.
1/3
2/3
Gastric ulcer
Billroth II gastrectomy for duodenal ulcer
Duodenum
1/3
Stoma
2/3
Duodenal ulcer
Rest of cut end of stomach closed to produce ‘valved’
Duodenal ulcer left in situ
anastomosis which narrows stoma and perhaps directs
Duodenal stump oversewn
pancreatico-biliary secretions to jejunum,
Fig.3.8 Billroth I and Billroth II gastrectomy
Reproduced from Essential Surgery Problems, Diagnosis and Management, 3rd edition, Burkitt HG and Quick CGR, Figure4., p.223. Copyright Elsevier 200
Burkitt HG, Quick CGR, Essential Surgery Problems, Diagnosis and Management, 3rd edition, 200, Elsevier.
56
https://t.me/medicina_free
CHAPTER 3 | STOMACH AND DUODENAL DISORDERS
5. C.Iron
• Anaemia post gastrectomy may be multifactorial– iron, B2, or folate deciency
• Hypochlorhydria post gastrectomy results in reduced iron absorption
• Folate deciency is exacerbated by B2 deciency
Iron deciency is the most common vitamin deciency post gastrectomy, and occurs approximately 0years before the onset of vitamin B2 deciency (because the body has substantial reserves of B2). Gastric acid is required for the solubilization of ferric iron to form ferrous iron. Therefore, hypochlorhydria post gastrectomy results in reduced iron absorption. Vitamin B2 deciency occurs because of the reduction in intrinsic factor, which is secreted by the parietal cells of the stomach. Folate deciency has also been documented, and may be exacerbated by vitamin B2 deciency because the latter is required to convert inactive methyltetrahydrofolic acid to the active tetrahydrofolic acid. Vitamin D deciency with subsequent osteoporosis has also been implicated.
Following partial gastrectomy, 30%– 40% of patients experience long- term side eects. The risk of malignant change in the gastric remnant is 3% over 5years. Dumping syndrome tends to present within three months of surgery, but can resolve within one year post- operatively. It occurs in 25%– 50% of patients, but causes signicant symptoms in 5%– 0%.
A Billroth II gastrectomy is the surgical procedure of choice for a duodenal ulcer, whereas the Billroth Iis used for a gastric ulcer.
Rogers C.Postgastrectomy nutrition. Nutr Clin Pract. 20;26:26– 36. Doi: 0.77/08845336400070.
6. C. Three years
• Extensive atrophic gastritis and intestinal metaplasia (IM) are precancerous conditions because they constitute the background in which dysplasia and intestinal- type gastric adenocarcinoma develop
• For adequate staging and grading, at least four non- targeted biopsies of two topographic sites should be taken; additional targeted biopsies of lesions should also be taken
• Helicobacter pylori eradication is important to slow progression to cancer
The histopathological slide (Fig. 3.9) demonstrates gastric body mucosa with an almost complete absence of specialized gastritis glands, extensive intestinal metaplasia, and focal pyloric metaplasia. No H.pylori organisms are seen.
High- risk features predisposing to GC include the following:
• Membership of a high- risk ethnic population (e.g. East Asian ethnicity)
• Residence in, or migration from, a high- risk geographic location
• Family history of GC
• Dysplasia on biopsy
• Extensive IM on biopsies; the extent of IM is probably more important than the metaplastic subtype
• Operative Link on Gastritis Assessment (OLGA) or Operative Link on Gastric Intestinal Metaplasia (OLGIM) Stage III or IV
Pyloric
inammatory inltrate
https://t.me/medicina_free
metaplasia
Extensive intestinal metaplasia
CHAPTER 3 | ANSWERS
Plasma cell rich
57
Fig.3.9 Histology specimen from stomach body
Image courtesy of Dr Eve Fryer, Consultant Histopathologist, Oxford University Hospitals NHS Foundation Trust
The European Society of Gastrointestinal Endoscopy (ESGE) recommends that patients with extensive atrophy and/ or intestinal metaplasia should receive follow- up oesophago- gastro­duodenoscopy assessment every three years after diagnosis. There is no specic treatment for atrophic gastritis or IM. However, H.pylori eradication may lead to partial regression of atrophic gastritis. Although it does not reverse intestinal metaplasia, it may slow progression to neoplasia.
Dinis- Ribeiro M etal. Management of precancerous conditions and lesions in the stomach (MAPS). Endoscopy. 202;44:74– 94. Doi:0.055/ s- 003- 2949.
7. C. Repeat the gastroscopy with excision of polyps >1cm
• Fundic gland polyps are the most prevalent type of gastric epithelial polyp
• The number, location and size of the largest polyp should be clearly documented
• Adenomatous polyps should be resected, when appropriate, because of the signicant malignant potential
Gastric epithelial polyps can be classied as three types:fundic gland polyps (FGPs), hyperplastic polyps, and adenomatous polyps. FGPs are the most prevalent type of epithelial polyp. They are typically small (<cm), multiple, and located in the fundus and body. Their colour is usually the same as the surrounding mucosa. They are not usually associated with an increased risk of cancer unless in the context of familial adenomatous polyposis (FAP). However, larger polyps (>cm) have been shown to be dysplastic in approximately 2% of patients. Routine tissue sampling of FGPs (<cm) is not required. Unlike hyperplastic and adenomatous polyps, there is no association with H.pylori infection. FGPs are associated with long- term PPI use, however, and regress once PPI treatment is stopped. One should question the diagnosis of FGPs if they appear ulcerated, >cm, or are in an antral location. Such atypical features warrant excision.
Hyperplastic polyps are typically small, single, or few in number. They are red, dome­shaped, and smooth. Associated with H.pylori infection, gastric atrophy and gastric intestinal metaplasia, these polyps regress on eradication of H.pylori. Hyperplastic polyps are potentially